Trial Profile
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2021
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Amgen; Onyx Pharmaceuticals
- 01 Feb 2021 Protocol of the trial was amended as cohort 1 was suspended due to serious adverse events and cohort four was added.
- 01 Feb 2021 Results (n=33) assessing safety of carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma, published in the American Journal of Hematology
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.